* Alza Corp., of Palo Alto, Calif., said it exercised an option to license from Therapeutic Discovery Corp., of Palo Alto, an OROS hydromorphone product for chronic pain. The drug is designed for once-a-day administration. Alza also said it will develop the product in collaboration with Knoll Pharmaceutical Co., of Mount Olive, N.J., a subsidiary of Knoll AG, of Ludwigshafen, Germany. Knoll AG is part of BASF AG, of Ludwigshafen. Financial terms of the deals were not disclosed.
* Discovery Therapeutics Inc., of Richmond, Va., said preliminary results from a Phase IIb trial of its dopamine agonist transdermal patch for Parkinson's disease showed the patch replaced oral administrations of dopamine agonists and reduced daily dosage of levodopa to control symptoms of the disease.
* Millennium Pharmaceuticals Inc., of Cambridge, Mass., said it completed its takeover of ChemGenics Pharmaceuticals Inc., also of Cambridge, in a stock swap valued at about $90 million. The merger of the two firms was reported in January. (See BioWorld Today, Jan. 22, 1997, p. 1.)
* QLT PhotoTherapeutics Inc., of Vancouver, British Columbia, filed a supplemental new drug application with the FDA for approval of Photofrin, a light-activated treatment, for lung cancer. Photofrin already is approved in the U.S. for esophageal cancer.